Table 1 |
||||
|
Characteristics of the Sample and its Subgroups at first clinic visit |
||||
|
Characteristic |
Total Sample |
Group 1 (G1) |
Group 2 (G2) |
P-value ¶ |
|
|
||||
|
Sample size (n) |
455 |
36 |
419 |
|
|
Sex: n (%) |
||||
|
Male |
334(73.4) |
33 (91.7) |
301 (71.8) |
0.127 |
|
Female |
121(26.6) |
3 (8.3) |
118 (28.2) |
|
|
HIV risk factor: n (%) |
||||
|
IDU * |
285(62.9) |
2 (5.7) |
283 (67.7) |
< 0.001 |
|
Heterosexual |
123(27) |
16 (44.4) |
107 (25.5) |
0.132 |
|
MSM ** |
23(5.1) |
4 (11.1) |
19 (4.5) |
< 0.999 ∥ |
|
MSMW ‡ |
8(1.8) |
6 (16.7) |
2 (0.5) |
< 0.001 ∥ |
|
Unknown |
16(3.5) |
8 (22.2) |
8 (2) |
< 0.001 ∥ |
|
AIDS criteria: n (%) |
||||
|
Yes § |
57(12.5) |
7 (19.4) |
50 (11.9) |
< 0.999 ∥ |
|
No |
398(87.5) |
29 (80.6) |
369 (88.1) |
|
|
Previous treatment: n (%) |
||||
|
Yes |
181(39.8) |
2 (5.6) |
179 (42.7) |
< 0.001 |
|
No |
274(60.2) |
34 (94.4) |
240 (57.3) |
|
|
CD4 (n° cel./mm3) |
352.08 ± 294.10 |
180.83 ± 230.85 |
366.90 ± 294.52 |
< 0.001 |
|
CD8 (n° cel./mm3) |
957.82 ± 597.10 |
963.38 ± 733.22 |
956.97 ± 583.73 |
< 0.999 |
|
Plasma viral load (log10) |
4.09 ± 1.22 |
4.51 ± 1.18 |
4.05 ± 1.22 |
0.451 |
|
HBsAg #: n (%) |
||||
|
Positive |
24(8.1) |
1 (4.5) |
23 (8.3) |
< 0.999 |
|
Negative |
274(91.9) |
21 (95.5) |
253 (91.7) |
|
|
Anti-HCV: n (%) |
||||
|
Positive |
197(56.8) |
3 (13.6) |
194 (65.1) |
< 0.001 |
|
Negative |
123(43.2) |
19 (86.4) |
104 (34.9) |
|
|
|
||||
|
¶ P value adjusted by Bonferroni procedure; * IDU: Injection drug user; ** MSM: Men who have sex with men; ∥ Fisher exact test; ‡ MSMW: Men who have sex with men or women; § AIDS criteria: Centers for Disease Control and Prevention (CDC) category C; # HBsAg: Hepatitis B superficial antigen |
||||
|
Nogueras et al. BMC Infectious Diseases 2006 6:159 doi:10.1186/1471-2334-6-159 |
||||
